5th Annual Protein Formulation Development and Drug Delivery Forum

5th Annual Protein Formulation Development and Drug Delivery Forum

09-06-2014 - 11-06-2014 Hotel Avenida Palace, Barcelona, Spain

The 5th Annual Protein Formulation Development and Drug Delivery Forum will delve into protein formulation and drug delivery innovations and update delegates with regulatory framework, which are considered to be some of the biggest challenges.

The 5th Annual Protein Formulation Development and Drug Delivery Forum will delve into protein formulation and drug delivery innovations and update delegates with regulatory framework, which are considered to be some of the biggest challenges.

Delegates will learn and benefit from case studies to minimise risks, time and cost expenditure.

Key Topics Include:

  • Streamline your strategies from pre-formulation to successful drug delivery
  • Integrate the regulatory guidelines from subvisible particles to manufacturing issues into your research development
  • Explore different approaches to effectively manage the recurring obstacles in formulation and drug delivery
  • Leverage your analytical skills to forecast your next steps and save on time and cost expenditure

Guest speakers include:

Carsten Olbrich
Director, Product Development & Laboratory Head
Bayer 

Jeffrey T. Blue
Director, Vaccine Drug Product Development
Merck 

Margarida Rodrigues
Senior Scientist
Novartis Pharma AG 

Martinus Capelle
Principal Scientist
Crucell, a Johnson & Johnson Company 

Reinhard Stidl
Senior Scientist, Toxicological Risk Assessments, Preclinical Pharmacology & Toxicology
Baxter Innovations GmbH 

Alexander Bepperling
Senior Scientist, Biophysical Characterisation
Sandoz 

Russell Burge
Application Scientist
Freeslate 

Paul Matejtschuk
Principal Scientist
National Institute for Biological Standards & Control (NIBSC), Medicines & Healthcare Products Regulatory Agency (MHRA), Healthcare Protection Agency (HPA) 

COMPANY SPOTLIGHT

Parexel

Parexel

Sobi

SOBI.jpg

Sobi (Swedish Orphan Biovitrum) is a Swedish company that manufactures recombinant protein drugs for the treatment of genetic diseases.

Back to top